Advancing agile genome editing innovations for the benefit of patients and our communities


Founded by pioneers of CRISPR biology

Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types.

about lab image


Leadership Team

Executive Leadership Team

Rachel Haurwitz photo

Rachel Haurwitz, Ph.D.

President and Chief Executive Officer

Steven Kanner photo

Steven Kanner, Ph.D.

Chief Scientific Officer

Barbara McClung photo

Barbara McClung, J.D.

Chief Legal Officer and Corporate Secretary

Jason O’Byrne photo

Jason O’Byrne

Chief Financial Officer

Senior Leadership Team

Cherry Thomas photo

Cherry Thomas, M.D.

Senior Vice President of Clinical Development

Elaine Alambra photo

Elaine Alambra

Vice President of Regulatory Affairs and Quality Assurance

Ryan Fischesser photo

Ryan Fischesser

Vice President of Finance and Controller

Chris Fuller photo

Chris Fuller, Ph.D.

Vice President of Informatics

Scott Gradia photo

Scott Gradia, Ph.D.

Vice President of Platform Research

Cindy Hayashi photo

Cindy Hayashi

Vice President of Human Resources

Justin Skoble photo

Justin Skoble, Ph.D.

Vice President of Technical Operations


Board of Directors


Scientific Advisory Board


Collaborations

We are committed to fostering strong partnerships to develop and advance genome-edited therapies. If you are interested in partnering with Caribou, please contact our team.

abbvie logo
leukemia & lymphoma society logo

Licenses

Caribou has an extensive CRISPR technology IP portfolio, including an exclusive license from The Regents of the University of California and the University of Vienna to the foundational CRISPR-Cas9 IP invented by Jennifer Doudna, Emmanuelle Charpentier, and their colleagues. Caribou licenses this CRISPR-Cas9 IP and certain of its own Cas9 IP to other companies for use in multiple market sectors including but not limited to research tools, transgenic research animals, internal research, diagnostics, and industrial biotechnology. For information regarding licensing, click here.

Caribou has entered into licenses with recognized leaders in many market sectors. Such licenses include:

Corteva Agriscience logo
Danisco US Inc. logo
Genus plc logo
Helmholtz Zentrum München logo
Integrated DNA Technologies, Inc. logo
Intellia Therapeutics, Inc. logo
The Jackson Laboratory logo
Medical Research Council logo
Novartis logo
Novome Biotechnologies, Inc. logo
Oxford Nanopore Technologies Ltd logo
RenOVAte Biosciences logo
Takara logo